JP2008533191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008533191A5 JP2008533191A5 JP2008502453A JP2008502453A JP2008533191A5 JP 2008533191 A5 JP2008533191 A5 JP 2008533191A5 JP 2008502453 A JP2008502453 A JP 2008502453A JP 2008502453 A JP2008502453 A JP 2008502453A JP 2008533191 A5 JP2008533191 A5 JP 2008533191A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- alkyl
- alaninyl
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 229910019142 PO4 Inorganic materials 0.000 claims 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 7
- 239000010452 phosphate Substances 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- UENGBOCGGKLVJJ-UHFFFAOYSA-N 2-chloro-1-(2,4-difluorophenyl)ethanone Chemical compound FC1=CC=C(C(=O)CCl)C(F)=C1 UENGBOCGGKLVJJ-UHFFFAOYSA-N 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 claims 2
- 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 claims 2
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0505781.5A GB0505781D0 (en) | 2005-03-21 | 2005-03-21 | Chemical compounds |
| GB0505781.5 | 2005-03-21 | ||
| PCT/GB2006/000932 WO2006100439A1 (en) | 2005-03-21 | 2006-03-16 | Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013097919A Division JP5863702B2 (ja) | 2005-03-21 | 2013-05-07 | 癌の治療における使用のためのヌクレオシド化合物のホスホルアミデート誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008533191A JP2008533191A (ja) | 2008-08-21 |
| JP2008533191A5 true JP2008533191A5 (enExample) | 2009-04-30 |
| JP5345381B2 JP5345381B2 (ja) | 2013-11-20 |
Family
ID=34531603
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502453A Expired - Fee Related JP5345381B2 (ja) | 2005-03-21 | 2006-03-16 | 癌の治療における使用のためのヌクレオシド化合物のホスホルアミデート誘導体 |
| JP2013097919A Expired - Fee Related JP5863702B2 (ja) | 2005-03-21 | 2013-05-07 | 癌の治療における使用のためのヌクレオシド化合物のホスホルアミデート誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013097919A Expired - Fee Related JP5863702B2 (ja) | 2005-03-21 | 2013-05-07 | 癌の治療における使用のためのヌクレオシド化合物のホスホルアミデート誘導体 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8263575B2 (enExample) |
| EP (1) | EP1866324B1 (enExample) |
| JP (2) | JP5345381B2 (enExample) |
| CN (2) | CN101175763A (enExample) |
| AT (1) | ATE471334T1 (enExample) |
| AU (1) | AU2006226182C1 (enExample) |
| BR (1) | BRPI0609704B8 (enExample) |
| CA (1) | CA2602324C (enExample) |
| CY (1) | CY1111538T1 (enExample) |
| DE (1) | DE602006014949D1 (enExample) |
| DK (1) | DK1866324T3 (enExample) |
| ES (1) | ES2348741T3 (enExample) |
| GB (1) | GB0505781D0 (enExample) |
| IL (1) | IL186104A (enExample) |
| MX (1) | MX2007011666A (enExample) |
| PL (1) | PL1866324T3 (enExample) |
| PT (1) | PT1866324E (enExample) |
| SI (1) | SI1866324T1 (enExample) |
| WO (1) | WO2006100439A1 (enExample) |
| ZA (1) | ZA200709011B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0623493D0 (en) * | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
| AU2012216500B2 (en) * | 2006-11-24 | 2013-06-20 | Katholieke Universiteit Leuven | Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| AR074897A1 (es) | 2008-12-23 | 2011-02-23 | Pharmasset Inc | Fosforamidatos de nucleosidos |
| CL2009002206A1 (es) | 2008-12-23 | 2011-08-26 | Gilead Pharmasset Llc | Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales. |
| MX2011006890A (es) | 2008-12-23 | 2011-07-20 | Pharmasset Inc | Analogos de nucleosidos. |
| BRPI1004575A2 (pt) | 2009-01-09 | 2016-04-05 | Inhibitex Inc | composto, composição farmacêutica, método de tratamento de infecções virais, método de separação dos diaestereômeros de fósforo |
| AP2012006535A0 (en) | 2010-03-31 | 2012-10-31 | Gilead Pharmasset Llc | Stereoselective synthesis of phosphorous containing actives |
| GB201016855D0 (en) * | 2010-10-06 | 2010-11-17 | Nucana Biomed Ltd | Chemical compounds |
| WO2012092484A2 (en) * | 2010-12-29 | 2012-07-05 | Inhibitex, Inc. | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
| US9095599B2 (en) | 2011-01-03 | 2015-08-04 | Nanjing Molecular Research, Inc. | O-(substituted benzyl) phosphoramidate compounds and therapeutic use |
| ES2569185T3 (es) | 2011-03-01 | 2016-05-09 | Nucana Biomed Limited | Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer |
| US9085599B2 (en) | 2011-03-16 | 2015-07-21 | Enanta Pharmaceuticals, Inc. | 2′allene-substituted nucleoside derivatives |
| AU2013346515B2 (en) * | 2012-11-16 | 2017-05-25 | NuCana plc | Process for preparing nucleoside prodrugs |
| EP3004130B1 (en) | 2013-06-05 | 2019-08-07 | Idenix Pharmaceuticals LLC. | 1',4'-thio nucleosides for the treatment of hcv |
| JP2017504572A (ja) * | 2013-11-27 | 2017-02-09 | アイデニクス・ファーマシューティカルズ・エルエルシー | 肝臓癌治療のためのヌクレオチド類 |
| US20170101431A1 (en) * | 2014-05-28 | 2017-04-13 | Idenix Pharmaceuticals Llc | Nucleoside derivatives for the treatment of cancer |
| AU2015265607A1 (en) * | 2014-05-28 | 2016-11-17 | Idenix Pharmaceuticals Llc | Nucleoside derivatives for the treatment of cancer |
| HRP20191461T1 (hr) | 2014-11-28 | 2019-11-15 | NuCana plc | Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja |
| FI3265102T3 (fi) | 2015-03-06 | 2025-10-31 | Atea Pharmaceuticals Inc | Beta-d-2'-deoksi-2'-alfa-fluori-2'-beta-c-substituoituja-2-modifioituja-n6-substituoituja puriininukleotideja hcv-hoitoa varten |
| EP3377512A4 (en) * | 2015-11-16 | 2019-09-18 | Ichorion Therapeutics, Inc. | Nucleic Acid PRODRUGS |
| GB201522764D0 (en) * | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
| GB201609600D0 (en) * | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| GB201609602D0 (en) * | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Chemical compounds |
| WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| PT3512863T (pt) | 2016-09-07 | 2022-03-09 | Atea Pharmaceuticals Inc | Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna |
| WO2018071675A1 (en) * | 2016-10-12 | 2018-04-19 | Georgetown University | Cd99 inhibitors and their uses |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201715011D0 (en) | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
| GB201720279D0 (en) | 2017-12-05 | 2018-01-17 | Nucana Biomed Ltd | Anticancer compounds |
| JP2020164521A (ja) * | 2019-03-29 | 2020-10-08 | 国立大学法人 長崎大学 | 抗ウィルス薬 |
| GB201904544D0 (en) | 2019-04-01 | 2019-05-15 | NuCana plc | Anticancer compounds |
| WO2021173713A1 (en) | 2020-02-27 | 2021-09-02 | Atea Pharmaceuticals, Inc. | Highly active compounds against covid-19 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| CN113549076B (zh) * | 2021-07-23 | 2022-12-06 | 中国药科大学 | 一种多取代嘌呤类化合物及其制备方法和应用 |
| WO2026151964A1 (en) | 2025-01-10 | 2026-07-16 | Atea Pharmaceuticals, Inc. | Compositions and use thereof in treating hepatitis e infections with beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR880000094B1 (ko) | 1984-12-07 | 1988-02-23 | 보령제약 주식회사 | 뉴클레오시드 유도체의 제조방법 |
| CA2004695C (en) | 1988-12-12 | 1999-08-10 | Rosanne Bonjouklian | Phospholipid nucleosides |
| DE4418690A1 (de) * | 1994-05-28 | 1996-01-11 | Boehringer Mannheim Gmbh | Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel |
| GB9505025D0 (en) * | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
| EP0821692B1 (en) | 1995-04-21 | 2006-01-11 | University Of South Florida | Immunopotentiating inosine monophosphate 5'-nucleotidase resistant derivatives and uses thereof |
| JP3761958B2 (ja) | 1996-03-12 | 2006-03-29 | 彰 松田 | ３′−カルバモイルアルキルヌクレオシド誘導体 |
| ES2172303T3 (es) * | 1998-01-23 | 2002-09-16 | Newbiotics Inc | Agentes terapeuticos obtenidos por catalisis enzimatica. |
| GB9821058D0 (en) * | 1998-09-28 | 1998-11-18 | Univ Cardiff | Chemical compound |
| JP4768909B2 (ja) | 2000-09-29 | 2011-09-07 | 扶桑薬品工業株式会社 | トポイソメラーゼ阻害剤 |
| US20030073618A1 (en) * | 2001-02-08 | 2003-04-17 | Kozhemyakin Leonid A. | Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof |
| DE10108851A1 (de) * | 2001-02-23 | 2002-09-12 | Resprotect Gmbh | Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten |
| WO2003000200A2 (en) * | 2001-06-22 | 2003-01-03 | Pharmasset Ltd. | β-2'-OR 3'-HALONUCLEOSIDES |
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| GB0401088D0 (en) * | 2004-01-19 | 2004-02-18 | Univ Cardiff | Phosphoramidate derivatives |
| US20070265222A1 (en) * | 2004-06-24 | 2007-11-15 | Maccoss Malcolm | Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection |
| CN101287472B (zh) * | 2005-08-15 | 2011-10-12 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物 |
-
2005
- 2005-03-21 GB GBGB0505781.5A patent/GB0505781D0/en not_active Ceased
-
2006
- 2006-03-16 PL PL06710096T patent/PL1866324T3/pl unknown
- 2006-03-16 ES ES06710096T patent/ES2348741T3/es not_active Expired - Lifetime
- 2006-03-16 CN CNA200680016708XA patent/CN101175763A/zh active Pending
- 2006-03-16 MX MX2007011666A patent/MX2007011666A/es active IP Right Grant
- 2006-03-16 CA CA2602324A patent/CA2602324C/en not_active Expired - Lifetime
- 2006-03-16 CN CN201410186829.5A patent/CN103936807A/zh active Pending
- 2006-03-16 ZA ZA200709011A patent/ZA200709011B/xx unknown
- 2006-03-16 PT PT06710096T patent/PT1866324E/pt unknown
- 2006-03-16 SI SI200630762T patent/SI1866324T1/sl unknown
- 2006-03-16 AT AT06710096T patent/ATE471334T1/de active
- 2006-03-16 AU AU2006226182A patent/AU2006226182C1/en not_active Ceased
- 2006-03-16 BR BRPI0609704A patent/BRPI0609704B8/pt not_active IP Right Cessation
- 2006-03-16 US US11/886,931 patent/US8263575B2/en not_active Expired - Fee Related
- 2006-03-16 DK DK06710096.6T patent/DK1866324T3/da active
- 2006-03-16 JP JP2008502453A patent/JP5345381B2/ja not_active Expired - Fee Related
- 2006-03-16 DE DE602006014949T patent/DE602006014949D1/de not_active Expired - Lifetime
- 2006-03-16 WO PCT/GB2006/000932 patent/WO2006100439A1/en not_active Ceased
- 2006-03-16 EP EP06710096A patent/EP1866324B1/en not_active Expired - Lifetime
-
2007
- 2007-09-20 IL IL186104A patent/IL186104A/en active IP Right Grant
-
2010
- 2010-09-10 CY CY20101100826T patent/CY1111538T1/el unknown
-
2013
- 2013-05-07 JP JP2013097919A patent/JP5863702B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013537203A5 (enExample) | ||
| JP2005523922A5 (enExample) | ||
| JP2008505157A5 (enExample) | ||
| JP2019512478A5 (enExample) | ||
| JP2010530881A5 (enExample) | ||
| JP2007511504A5 (enExample) | ||
| JP2008528447A5 (enExample) | ||
| JP2004516314A5 (enExample) | ||
| CA2565660A1 (en) | Ortho substituted aryl or heteroaryl amide compounds | |
| JP2009535307A5 (enExample) | ||
| JP2008510828A5 (enExample) | ||
| JP2009504763A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2006514012A5 (enExample) | ||
| JP2008510770A5 (enExample) | ||
| CA2545427A1 (en) | Selective kinase inhibitors | |
| JP2011526917A5 (enExample) | ||
| JP2014503574A5 (enExample) | ||
| JP2005539088A5 (enExample) | ||
| JP2002516817A5 (enExample) | ||
| JP2007501809A5 (enExample) | ||
| JP2018530582A5 (enExample) | ||
| JP2003306481A5 (enExample) | ||
| JP2009520695A5 (enExample) | ||
| WO2008056264A3 (en) | Novel nucleotide analogues as percursor molecules for antivirals |